Tokyo-based Arigen Out-licenses Ulcer Drug To Korean CJ CheilJedang
This article was originally published in PharmAsia News
Executive Summary
Tokyo-based biotech venture firm aRigen Pharmaceutical out-licensed the rights to ulcer drug ARH-1029 in Korea to Seoul-based Korean food and drug conglomerate CJ CheilJedang